Primary prophylaxis for children with severe congenital factor VII deficiency - Clinical and laboratory assessment

Area of Science:

• Hematology
• Pediatric Medicine
• Rare Diseases

Background:

• Severe congenital factor VII (FVII) deficiency is a rare bleeding disorder.
• Optimal prophylactic dosing regimens and intervals for FVII deficiency remain undefined.
• Evidence-based data on long-term prophylaxis in high-risk pediatric patients is limited.

Purpose of the Study:

• To evaluate the safety and efficacy of long-term primary prophylaxis in children with severe FVII deficiency and high bleeding risk.
• To assess the utility of FVII activity and thrombin generation assays as surrogate markers for prophylaxis effectiveness.
• To present clinical experience with prophylactic recombinant activated factor VII (rFVIIa) administration.

Main Methods:

• Long-term clinical follow-up of four children with familial FVII deficiency.
• Prophylactic administration of rFVIIa at 15-30μg/kg/dose, 2-3 times weekly since infancy.
• Monitoring of FVII activity and thrombin generation at various time points post-rFVIIa administration.

Main Results:

• Neither FVII activity nor thrombin generation parameters predicted the impact of prophylaxis.
• These laboratory markers declined within 24 hours post-rFVIIa administration.
• No surrogate markers were identified to assess optimal treatment frequency.

Conclusions:

• Early primary prophylaxis with rFVIIa, as administered in this cohort, was safe and effective in children with severe FVII deficiency.
• Comprehensive laboratory assessment and long clinical follow-up are crucial.
• Further research is needed to define optimal prophylactic strategies.